Company Description
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases.
It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.
The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection.
It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections.
Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections.
The company is headquartered in Bothell, Washington.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Dr. Sam Lee Ph.D. |
Contact Details
Address: 19805 N. Creek Parkway Bothell, Washington 98011 United States | |
| Phone | (786) 459-1831 |
| Website | cocrystalpharma.com |
Stock Details
| Ticker Symbol | COCP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001412486 |
| CUSIP Number | 19188J300 |
| ISIN Number | US19188J4094 |
| Employer ID | 35-2528215 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| James J. Martin CPA, M.B.A. | Co-Chief Executive Officer, Chief Financial Officer and Corporate Secretary |
| Dr. Sam Lee Ph.D. | Co-Founder, Co-Chief Executive Officer and President |
| Dr. Roger D. Kornberg Ph.D. | Co-Founder, Chairman of the Board, Chief Scientist and Chairman of Scientific Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 28, 2024 | 8-K | Current Report |
| Jun 20, 2024 | 8-K | Current Report |
| May 13, 2024 | 8-K | Current Report |
| May 13, 2024 | 10-Q | Quarterly Report |
| May 7, 2024 | DEF 14A | Other definitive proxy statements |
| May 1, 2024 | 8-K | Current Report |
| Apr 26, 2024 | PRE 14A | Other preliminary proxy statements |
| Apr 17, 2024 | 10-K/A | [Amend] Annual report |
| Mar 28, 2024 | 10-K | Annual Report |
| Mar 28, 2024 | 8-K | Current Report |